However, it has also been reported that about 45% ER−/PR+ breast tumor patients and 10% ER−/PR− tumor patients responded to tamoxifen treatment (Reviewed in [33]), suggesting that a subset of ER-negative breast cancer still responses to antiestrogen therapy. This evidence concerns the gene ESR1 and neoplasm.